PMS Registry
Company Name
Novartis (Taiwan) Co., Ltd.
Protocol Number
Title of Study
A Prospective, Non-interventional, Multi-center, Surveillance Study to Observe the Tolerability of Exjade® (Deferasirox) in Patients with Myelodysplastic Syndrome (MDS) for Chronic Transfusion-Related Iron Overload
Primary Objective
To explore tolerability of Exjade® as chelation therapy through measuring AE-related discontinuation rate in routine clinical practice in MDS patients at 6 months.
Number of Sites
Period of Study
From:Aug.1, 2015 to:Aug. 31, 2019
Number of Patients
IRB Approval Date
Sep. 17, 2015 (1st IRB approval date)
Publication Plan / Date
Aug. 31, 2020